- references:
  - doi: 10.1038/s41586-020-2380-z
    firstAuthor:
      surname: Ju
      givenNames: Bin
    year: 2020
    journal: Nature
  antibodies:
  - name: P2B-2F6
    ec50: 410
    pdb: RBD (7BWJ)
    species: Human
    IGHV: IGHV4-38-2
    PcntMutH: 1%
    CDRH3Len: 20
    IGHJ: IGHJ3
    IGLV: IGLV2-8
    PcntMutL: 0%
    CDRL3Len: 10
    IGLJ: IGLJ3
  - name: P2C-1A13
    ec50: 280
  - name: P2C-1F11
    ec50: 30
  source:
  - SARS-2 B cells
  - RBD
  description: |-
    P2B-2F6, P2C-1F11, and P2C-1A13 are ACE2-competing mAbs. P2B-2F6 is predicted to bind with RBD in both its up and down configurations.
- references:
  - doi: 10.1038/s41586-020-2381-y
    firstAuthor:
      surname: Shi
      givenNames: Rui
    year: 2020
    journal: Nature
  antibodies:
  - name: CB6
    ec50: 835
    pdb: RBD (7C01)
    species: Human
    IGHV: IGHV3-66
    PcntMutH: 3%
    CDRH3Len: 13
    IGHJ: IGHJ4
    IGLV: IGKV1-39
    PcntMutL: 2%
    CDRL3Len: 11
    IGLJ: IGKJ2
  source:
  - SARS-2 B cells
  - RBD
  description: |-
    CB6 is an ACE2-competing mAb. It has been shown to reduice virus levels and lung pathology when administered 1 day before and 1 day after infection of rhesus macaques. Its Fc receptor has been mutated (LALA) to prolong its half-life. The same mAb or a similar one called JS016 is being evaluated in a phase I clinical trial.
- references:
  - doi: 10.1038/s41586-020-2349-y
    firstAuthor:
      surname: Pinto
      givenNames: Dora
    year: 2020
    journal: Nature
  antibodies:
  - name: S309
    ec50: 80
    pdb: S trimer (6WPS, 6WPT)
    species: Human
    IGHV: IGHV1-18
    PcntMutH: 6%
    CDRH3Len: 20
    IGHJ: IGHJ4
    IGLV: IGKV3-20
    PcntMutL: 3%
    CDRL3Len: 8
    IGLJ: IGKJ4
  source:
  - SARS-1 B cells
  - RBD & S trimer
  description: |-
    S309 is a non-ACE2-competing mAb that binds to the RBD core region and cross-neutralizes SARS-1. It binds to RBD in its open and closed configuration and it binds to a unique proteoglycan epitope at N343.
- references:
  - doi: 10.1038/s41423-020-0426-7
    firstAuthor:
      surname: Chen
      givenNames: Xiangyu
    year: 2020
    journal: Cellular & Molecular Immunology
    journalShort: Cell Mol Immunol
  antibodies:
  - name: 311mab-31B5
    ec50: 34
    ec50Note: PV
  - name: 311mab-32D4
    ec50: 70
    ec50Note: PV
  source:
  - SARS-2 B cells
  - RBD
  description: |-
    311mab-31B5 and 311mab-32D4 are ACE2-competing mAbs.
- references:
  - doi: 10.1038/s41467-020-16256-y
    firstAuthor:
      surname: Wang
      givenNames: Chunyan
    year: 2020
    journal: Nature Communications
    journalShort: Nat Commun
  antibodies:
  - name: 47D11
    ec50: 570
  source:
  - H2L2 mice immunized with S trimer of OC43, SARS, and MERS
  description: |-
    47D11 is a non-ACE2-competing mAb that cross-neutralizes SARS-1.
- references:
  - doi: 10.1126/science.abc5902
    firstAuthor:
      surname: Brouwer
      givenNames: Philip J. M.
    year: 2020
    journal: Science
  - doi: 10.1101/2020.07.26.222232
    firstAuthor:
      surname: Wu
      givenNames: Nicholas C.
    year: 2020
    journal: bioRxiv
  - doi: 10.1101/2020.08.02.233536
    firstAuthor:
      surname: Liu
      givenNames: Hejun
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: COVA1-16
    ec50: 745
    species: Human
    IGHV: IGHV1-46
    PcntMutH: 1%
    CDRH3Len: 22
    IGHJ: IGHJ1
    IGLV: IGKV1-33
    PcntMutL: 2%
    CDRL3Len: 9
    IGLJ: IGKJ4
  - name: COVA1-18
    ec50: 7
    species: Human
    IGHV: IGHV3-66
    PcntMutH: 0%
    CDRH3Len: 12
    IGHJ: IGHJ4
    IGLV: IGLV7-46
    PcntMutL: 4%
    CDRL3Len: 9
    IGLJ: IGLJ3
  - name: COVA2-15
    ec50: 9
    species: Human
    IGHV: IGHV3-23
    PcntMutH: 3%
    CDRH3Len: 22
    IGHJ: IGHJ4
    IGLV: IGKV2-30
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ2
  - name: COVA2-39
    ec50: 54
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 3%
    CDRH3Len: 17
    IGHJ: IGHJ3
    IGLV: IGLV2-23
    PcntMutL: 1%
    CDRL3Len: 10
    IGLJ: IGLJ3
  - name: COVA2-4
  source:
  - SARS-2 B cells
  - S trimer
  description: |-
    COVA1-16, COVA1-18, COVA2-04, COVA2-15, and COVA2-39 are ACE2-competing mAbs. COVA1-16 cross neutralizes SARS-CoV-1. It competes with ACE2 indirectly via steric hindrance. It binds to RBD in the up configuration, likely bivalently. COVA2-4 and COVA2-39 approach RBD from different angles. COVA2-4 contacts more ACE2-binding residues than COVA2-39 (11 vs. 16 of 17). COVA2-15 appears to bind ACE2 in its up and down configuration.
- references:
  - doi: 10.1126/science.abc7520
    firstAuthor:
      surname: Rogers
      givenNames: Thomas F.
    year: 2020
    journal: Science
  - doi: 10.1126/science.abd2321
    firstAuthor:
      surname: Yuan
      givenNames: Meng
    year: 2020
    journal: Science
  antibodies:
  - name: CC12.1
    ec50: 46
    pdb: RBD + CR3022 (6XC3)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 2%
    CDRH3Len: 11
    IGHJ: IGHJ6
    IGLV: IGKV1-9
    PcntMutL: 2%
    CDRL3Len: 11
    IGLJ: IGKJ3
  - name: CC12.3
    pdb: RBD + CR3022 (6XC7)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 4%
    CDRH3Len: 11
    IGHJ: IGHJ4
    IGLV: IGKV3-20
    PcntMutL: 0%
    CDRL3Len: 9
    IGLJ: IGKJ2
  source:
  - SARS-2 B cells
  - RBD & S trimer
  description: |-
    CC12.1 and CC12.3 bind the ACE2-binding site with the same angle of approach. CC12.1 and CC12.3 bind 15 and 11 ACE2-binding residues, respectively. Both bind only in the open configuration. CC12.1 reduced weight loss in a hamster prevention model.
- references:
  - doi: 10.1016/j.cell.2020.05.025
    firstAuthor:
      surname: Cao
      givenNames: Yunlong
    year: 2020
    journal: Cell
  - doi: 10.1101/2020.07.09.195263
    firstAuthor:
      surname: Du
      givenNames: Shuo
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: BD-23
    pdb: S Trimer (7BYR)
  - name: BD-368-2
    ec50: 15
    pdb: S Trimer (7CHH, Pending)
  - name: BD-503
    ec50: 140
  - name: BD-503
    ec50: 140
  - name: BD-515
    ec50: 200
  - name: BD-602
    ec50Note: PV
    ec50: 11
  - name: BD-604
    ec50: 5
    pdb: RBD (7CH4, Pending)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 5%
    CDRH3Len: 11
    IGHJ: IGHJ6
    IGLV: ''
    PcntMutL: ''
    CDRL3Len:
    IGLJ: ''
  - name: BD-606
    ec50: 6
  - name: BD-612
    ec50: 18
  - name: BD-617
    ec50: 9
  - name: BD-629
    ec50: 4
    pdb: RBD (7CH5, Pending)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 4%
    CDRH3Len: 11
    IGHJ: IGHJ4
    IGLV: ''
    PcntMutL: ''
    CDRL3Len:
    IGLJ: ''
  - name: BD-632
    ec50: 17
  source:
  - SARS-2 B cells
  - RBD & S trimer
  description: |-
    BD-368-2 is an ACE2-competing mAb that can occupy all three RBDs simultaneously regardless of its configuration. It also does not compete with the ACE2-competing mAbs encoded by VH3-53/66. BD-604. BD-629, and BD-236 are ACE2-competing mAbs that bind RBD in its up configuration. BD-23 is an ACE2-competing mAb that binds RBD in its down configuration. BD-368-2 reduced weight loss and virus levels in a mouse treatment and prevention model.
- references:
  - doi: 10.1126/science.abc6952
    firstAuthor:
      surname: Chi
      givenNames: Xiangyang
    year: 2020
    journal: Science
  antibodies:
  - name: 0304-3H3
    ec50: 40
    species: Human
    IGHV: IGHV4-59
    PcntMutH: 4%
    CDRH3Len: 18
    IGHJ: IGHJ2
    IGLV: IGKV3-15
    PcntMutL: 2%
    CDRL3Len: 10
    IGLJ: IGKJ1
  - name: 4A8
    ec50: 610
    species: Human
    IGHV: IGHV1-24
    PcntMutH: 3%
    CDRH3Len: 21
    IGHJ: IGHJ6
    IGLV: IGKV2-24
    PcntMutL: 2%
    CDRL3Len: 9
    IGLJ: IGKJ3
  source:
  - SARS-2 B cells
  - S trimer
  description: |-
    4A8 binds the NTD. The mechanism of 0304-3H3 binding is uncertain.
- references:
  - doi: 10.1126/science.abc7424
    firstAuthor:
      surname: Wec
      givenNames: Anna Z.
    year: 2020
    journal: Science
  antibodies:
  - name: ADI-55688
    ec50: 190
  - name: ADI-55689
    ec50: 100
  - name: ADI-56000
    ec50: 120
  - name: ADI-56046
    ec50: 100
  source:
  - SARS-1 B cells
  - S tetramer
  description: |-
    ADI-55689 cross-neutralizes SARS-1 and competes with ACE2 but not CR3022. It binds at the edge of the ACE2 binding site. ADI-56046 also cross neutralizes SARS-1 and competes with ACE2 but binds further away from the tip of the RBD and causes it to compete with CR3022.
- references:
  - doi: 10.1126/science.abc2241
    firstAuthor:
      surname: Wu
      givenNames: Yan
    year: 2020
    journal: Science
  antibodies:
  - name: B38
    ec50: 180
    pdb: RBD (7BZ5)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 1%
    CDRH3Len: 9
    IGHJ: IGHJ6
    IGLV: IGKV1-9
    PcntMutL: 2%
    CDRL3Len: 10
    IGLJ: IGKJ2
  - name: H4
    ec50: 900
    species: Human
    IGHV: IGHV1-2
    PcntMutH: 0%
    CDRH3Len: 19
    IGHJ: IGHJ2
    IGLV: IGKV2-40
    PcntMutL: 2%
    CDRL3Len: 9
    IGLJ: IGKJ4
  source:
  - SARS-2 B cells
  - RBD
  description: |-
    H4 and B38 are ACE2-competing mAbs that bind to non-overlapping epitopes. Both mAbs have been shown to reduce lung pathology and virus levels in a mouse treatment model.
- references:
  - doi: 10.1126/science.abd0827
    firstAuthor:
      surname: Hansen
      givenNames: Johanna
    year: 2020
    journal: Science
  - doi: 10.1126/science.abd0831
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: Science
  - doi: 10.1101/2020.08.02.233320
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: REGN10933
    ec50: 8
    pdb: RBD (6XDG)
    species: Human
    IGHV: IGHV3-11
    PcntMutH: 3%
    CDRH3Len: 13
    IGHJ: IGHJ4
    IGLV: IGKV1-33
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ4
  - name: REGN10934
    ec50: 4.5
    species: Human
    IGHV: IGHV3-15
    PcntMutH: 1%
    CDRH3Len: 11
    IGHJ: IGHJ2
    IGLV: IGKV1-33
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ1
  - name: REGN10987
    ec50: 6
    pdb: RBD (6XDG)
    species: Human
    IGHV: IGHV3-30
    PcntMutH: 3%
    CDRH3Len: 13
    IGHJ: IGHJ4
    IGLV: IGLV2-14
    PcntMutL: 3%
    CDRL3Len: 10
    IGLJ: IGLJ3
  - name: REGN10989
    ec50: 1.1
    species: Human
    IGHV: IGHV1-2
    PcntMutH: 6%
    CDRH3Len: 16
    IGHJ: IGHJ5
    IGLV: IGLV2-14
    PcntMutL: 4%
    CDRL3Len: 10
    IGLJ: IGLJ3
  source:
  - Humanized mice immunized with S boosted with RBD
  description: |-
    REGN10933 and REGN10987 are ACE2=competing mAbs that bind to non-overlapping RBD epitopes. This combination of mAbs also reduce weight loss, lung pathology, and virus levels in mouse treatment and prevention models.
- references:
  - doi: 10.1038/s41586-020-2456-9
    firstAuthor:
      surname: Robbiani
      givenNames: Davide F.
    year: 2020
    journal: Nature
  - doi: 10.1016/j.cell.2020.06.025
    firstAuthor:
      surname: Barnes
      givenNames: Christopher O.
    year: 2020
    journal: Cell
  - doi: 10.1101/2020.07.21.214759
    firstAuthor:
      surname: Weisblum
      givenNames: Yiska
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: C102
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 3%
    CDRH3Len: 11
    IGHJ: IGHJ4
    IGLV: IGKV3-20
    PcntMutL: 0%
    CDRL3Len: 9
    IGLJ: IGKJ1
  - name: C105
    ec50: 26
    pdb: S trimer (6XCM, 6XCN)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 1%
    CDRH3Len: 12
    IGHJ: IGHJ4
    IGLV: IGLV2-8
    PcntMutL: 1%
    CDRL3Len: 11
    IGLJ: IGLJ3
  - name: C121
    ec50: 1.6
    species: Human
    IGHV: IGHV1-2
    PcntMutH: 2%
    CDRH3Len: 22
    IGHJ: IGHJ6
    IGLV: IGLV2-23
    PcntMutL: 0%
    CDRL3Len: 10
    IGLJ: IGLJ3
  - name: C135
    ec50: 3
    species: Human
    IGHV: IGHV3-30
    PcntMutH: 4%
    CDRH3Len: 12
    IGHJ: IGHJ4
    IGLV: IGKV1-5
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ1
  - name: C144
    ec50: 2.5
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 3%
    CDRH3Len: 25
    IGHJ: IGHJ4
    IGLV: IGLV2-14
    PcntMutL: 1%
    CDRL3Len: 10
    IGLJ: IGLJ1
  source:
  - SARS-2 B cells
  - RBD
  description: |-
    C105, C121, C135, and C144 are ACE2-competing mAbs. C105 binds 2 or 3 RBDs in the up configuration. C135 and C144 bind to RBD's up and down configurations.
- references:
  - doi: 10.1016/j.celrep.2020.107918
    firstAuthor:
      surname: Wan
      givenNames: Jinkai
    year: 2020
    journal: Cell Reports
  antibodies:
  - name: 414-1
    ec50: 263
  source:
  - SARS-2 B cells
  - RBD & S trimer
  description: |-
    414-1 is an ACE2-competing mAb
- references:
  - doi: 10.1038/s41586-020-2571-7
    firstAuthor:
      surname: Liu
      givenNames: Lihong
    year: 2020
    journal: Nature
  antibodies:
  - name: 1-20
    ec50: 7.5
  - name: 1-57
    ec50: 7.5
  - name: 2-15
    ec50: 0.8
  - name: 2-17
    ec50: 6
  - name: 2-7
    ec50: 3
  - name: 4-8
    ec50: 9
    pdb: S trimer
  - name: 5-24
    ec50: 7.5
  source:
  - SARS-2 B cells
  - S trimer
  description: |-
    2-4 ia an ACE2-competing mAb that binds RBD in its down position. In a low-resolution image 2-43 appears to bind to a quartenrary epitope at the top of spike with binding to adjacent S1 protomers. 4-8 binds to NTD. 2-15 is an ACE3-competing mAb that reduced lung virus levels in a hamster prevention model.
- references:
  - doi: 10.1038/s41586-020-2548-6
    firstAuthor:
      surname: Zost
      givenNames: Seth J.
    year: 2020
    journal: Nature
  antibodies:
  - name: COV2-2130
    ec50: 105
    species: Human
    IGHV: IGHV3-15
    PcntMutH: 4%
    CDRH3Len: 22
    IGHJ: IGHJ4
    IGLV: IGKV4-1
    PcntMutL: 4%
    CDRL3Len: 8
    IGLJ: IGKJ4
  - name: COV2-2196
    ec50: 15
    species: Human
    IGHV: IGHV1-58
    PcntMutH: 2%
    CDRH3Len: 16
    IGHJ: IGHJ3
    IGLV: IGKV3-20
    PcntMutL: 0%
    CDRL3Len: 10
    IGLJ: IGKJ1
  - name: COV2-2381
    species: Human
    IGHV: IGHV1-58
    PcntMutH: 2%
    CDRH3Len: 16
    IGHJ: IGHJ3
    IGLV: IGKV3-20
    PcntMutL: 2%
    CDRL3Len: 10
    IGLJ: IGKJ1
  source:
  - SARS-2 B cells
  - RBD & S trimer
  description: |-
    COV2-2196 and COV2-2130 are ACE2-competing mAbs that bind to nonoverlapping RBD epitopes. COV2-2196 binds RBD in the configuration; COV2-2130 binds RBD in the up and down configuration. Each mAb reduces weight loss and lung virus levels in a mouse prevention model. COV2-2196 redices lung virus levels in rhesus macaques.
- references:
  - doi: 10.1016/j.cell.2020.06.044
    firstAuthor:
      surname: Kreer
      givenNames: Christoph
    year: 2020
    journal: Cell
  antibodies:
  - name: FnC1t2p1_D4
    ec50: 100
    ec50Note: IC100
  - name: HbnC3t1p1_C6
    ec50: 100
    ec50Note: IC100
  - name: MnC2t1p1_A3
    species: Human
    IGHV: IGHV3-66
    PcntMutH: 3%
    CDRH3Len: 13
    IGHJ: IGHJ4
    IGLV: IGKV1D-12
    PcntMutL: 0%
    CDRL3Len: 9
    IGLJ: IGKJ1
  - name: MnC2t2p1_C11
    ec50: 100
    ec50Note: IC100
    species: Human
    IGHV: IGHV1-69
    PcntMutH: 3%
    CDRH3Len: 23
    IGHJ: IGHJ5
    IGLV: IGKV1-39
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ2
  - name: MnC4t2p1_B3
    ec50: 100
    ec50Note: IC100
    species: Human
    IGHV: IGHV3-9
    PcntMutH: 10%
    CDRH3Len: 17
    IGHJ: IGHJ2
    IGLV: IGKV1-12
    PcntMutL: 4%
    CDRL3Len: 9
    IGLJ: IGKJ3
  source:
  - SARS-2 B cells
  - S trimer
  description: |-
    None
- references:
  - doi: 10.1371/journal.pmed.0030237
    firstAuthor:
      surname: ter Meulen
      givenNames: Jan
    year: 2006
    journal: PLoS Medicine
    journalShort: PLoS Med
  - doi: 10.1126/science.abb7269
    firstAuthor:
      surname: Yuan
      givenNames: Meng
    year: 2020
    journal: Science
  - doi: 10.1016/j.chom.2020.06.010
    firstAuthor:
      surname: Huo
      givenNames: Jiandong
    year: 2020
    journal: Cell Host & Microbe
  antibodies:
  - name: CR3022
    ec50: 114
    pdb: "RBD (6W41, 6YLA, 6YM0, 6YOR)\nS trimer (6Z97)"
    species: Human
    IGHV: IGHV5-51
    PcntMutH: 9%
    CDRH3Len: 12
    IGHJ: IGHJ6
    IGLV: IGKV4-1
    PcntMutL: 3%
    CDRL3Len: 9
    IGLJ: IGKJ1
  source:
  - SARS-1 scFv phage display / Irradiated SARS-1
  description: |-
    CR3022 is a SARS-1 cross-reacting mAb that binds to a non-competing RBD epitope accessible only when the RBD is in the up configuration.
- references:
  - doi: 10.1101/2020.05.13.093088
    firstAuthor:
      surname: Li
      givenNames: Wei
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: ab1
    ec50: 195
  source:
  - 'Phage display: Na√Øve B cell Fab & scFv libraries'
  - RBD panning
  description: |-
    ab1 is an ACE2-competing mAb that has been shown to reduce lung virus levels when administered prophylatically in a mouse model.
- references:
  - doi: 10.4049/jimmunol.2000583
    firstAuthor:
      surname: Alsoussi
      givenNames: Wafaa B.
    year: 2020
    journal: The Journal of Immunology
    journalShort: J.I.
  - doi: 10.1016/j.cell.2020.06.011
    firstAuthor:
      surname: Hassan
      givenNames: Ahmed O.
    year: 2020
    journal: Cell
  antibodies:
  - name: 1B07
    ec50: 37
    species: Mouse
    IGHV: IGHV2-9-1
    PcntMutH: 0%
    CDRH3Len: 15
    IGHJ: IGHJ4
    IGLV: IGLV1
    PcntMutL: 2%
    CDRL3Len: 9
    IGLJ: IGLJ3
  - name: 2B04
    ec50: 1.5
    species: Mouse
    IGHV: IGHV2-9-1
    PcntMutH: 3%
    CDRH3Len: 14
    IGHJ: IGHJ4
    IGLV: IGLV1
    PcntMutL: 0%
    CDRL3Len: 9
    IGLJ: IGLJ1
  - name: 2H04
    ec50: 300
    species: Mouse
    IGHV: IGHV1-55
    PcntMutH: 6%
    CDRH3Len: 13
    IGHJ: IGHJ2
    IGLV: IGKV5-48
    PcntMutL: 4%
    CDRL3Len: 9
    IGLJ: IGKJ5
  source:
  - Plasmablasts from mice immunized with RBD followed by trimeric S boosting
  - humanized
  description: |-
    2B04 and 1B07 (but not 2H04) are ACE2-competing mAbs. 2B04 and 1B07 (but to a much lesser extent 2H04) also reduced weight loss, lung pathology, and virus levels in a mouse prevention model.
- references:
  - doi: 10.1126/science.abc5881
    firstAuthor:
      surname: Lv
      givenNames: Zhe
    year: 2020
    journal: Science
  antibodies:
  - name: H014
    ec50: 570
  source:
  - Phage display
  - Spleen Ab library from mice immunized with SARS-CoV RBD
  - SARS-CoV-2 RBD panning
  - humanized
  description: |-
    H014 is an ACE2-competing mAb that binds to RBD in its up configuration.
- references:
  - doi: 10.1016/j.immuni.2020.06.001
    firstAuthor:
      surname: Seydoux
      givenNames: Emilie
    year: 2020
    journal: Immunity
  - doi: 10.1101/2020.06.12.148692
    firstAuthor:
      surname: Hurlburt
      givenNames: Nicholas K.
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: CV30
    ec50: 1650
    pdb: RBD (6XE1)
    species: Human
    IGHV: IGHV3-53
    PcntMutH: 2%
    CDRH3Len: 12
    IGHJ: IGHJ6
    IGLV: IGKV3-20
    PcntMutL: 0%
    CDRL3Len: 9
    IGLJ: IGKJ2
  - name: CV30-GermLine
  source:
  - SARS-2 B cells
  - Trimeric spike & RBD
  description: |-
    CV30 is an ACE2 competing mAb, which binds to a high proportion of the ACE2-binding residues.
- references:
  - doi: 10.1038/s41594-020-0480-y
    firstAuthor:
      surname: Zhou
      givenNames: Daming
    year: 2020
    journal: Nature Structural & Molecular Biology
    journalShort: Nat Struct Mol Biol
  - doi: 10.1038/s41594-020-0469-6
    firstAuthor:
      surname: Huo
      givenNames: Jiangdong
    year: 2020
    journal: Nature Structural & Molecular Biology
    journalShort: Nat Struct Mol Biol
  antibodies:
  - name: EY6A
    ec50: 70
    pdb: "Nanobody (H11-H4) / RBD (6ZCZ)\nRBD (6ZER)\nTrimeric spike (6ZDH)\nDisordered\
      \ spike (6ZDG, 6ZFO)"
    species: Human
    IGHV: IGHV3-30-3
    PcntMutH: 3%
    CDRH3Len: 14
    IGHJ: IGHJ4
    IGLV: IGKV1-39
    PcntMutL: 0%
    CDRL3Len: 10
    IGLJ: IGKJ4
  - name: H11-H4
    ec50: 90
    pdb: CR3022 / RBD (6ZH9) (Huo)
    species: Alpaca
    IGHV: IGHV3-3
    PcntMutH: 8%
    CDRH3Len: 20
    IGHJ: IGHJ4
    IGLV: ''
    PcntMutL: ''
    CDRL3Len:
    IGLJ: ''
  source:
  - SARS-CoV-2 plasmablasts
  - ELISA S1 & Spike
  description: |-
    EY6A is a non-ACE2 competing mAb that competes with CR3022. CHECK SARS-1
- references:
  - doi: 10.1101/2020.07.14.203414
    firstAuthor:
      surname: Wang
      givenNames: Bei
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: 1F6
  - name: 2H4
  - name: 3D11
  - name: 3F11
  - name: 5A6
    ec50: 141
    pdb: Trimeric Spike
  - name: 6F8
  source:
  - Fab phage display library created from healthy human B cells selected for RBD
    binding.
  description: |-
    5A6 is an ACE2-competing mAb that binds bivalently to one RBD in the up configion and another in the down configuration.
- references:
  - doi: 10.1101/2020.08.15.252320
    firstAuthor:
      surname: Kreye
      givenNames: Jakob
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: CV07-209
    ec50: 3.1
    pdb: RBD (6XKQ, pending)
  - name: CV08-270
  source:
  - SARS-2 B cells
  - ELISA for RBD binding
  description: |-
    CV07-209 is an ACE2 competing mAb. CV07-270's epitope mimimally overlaps with ACE2 binding residues. CV07-209 reduces weight loss, lung pathology, and virus levels in a hamster prevention and treatment model.
- references:
  - doi: 10.1038/s41467-020-18058-8
    firstAuthor:
      surname: Ejemel
      givenNames: Monir
    year: 2020
    journal: Nature Communications
    journalShort: Nat Commun
  antibodies:
  - name: mAb362 (IgA)
  - name: mAb362 (IgG)
  - name: mAb362 (dimeric IgA)
  - name: mAb362 (secretory IgA)
  source:
  - Spleen cells from transgenic HuMAb mice immunized with SARS-1 S
  - Screened for binding to SARS-2 RBD.
  description: |-
    ACE2 competing; Can only bind in the open configuration. Cross-neutralizes S1; Mutational scanning to identify binding residues
- references:
  - doi: 10.1038/s41467-020-18159-4
    firstAuthor:
      surname: Noy-Porat
      givenNames: Tal
    year: 2020
    journal: Nature Communications
    journalShort: Nat Commun
  antibodies:
  - name: MD65
    ec50: 220
  source:
  - Human B cell phage display scFv libraries from acute and convalescent sera selected
    for RBD and S1 binding.
  description: |-
    MD65 is an ACE2-competing mAb
